|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000198681 |
Summary for MAGEA1 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000198681 | Gene symbol | MAGEA1 |
| Gene name | MAGE family member A1 | |
| HGNC | 6796 | |
| Entrez ID | 4100 | |
| Gene type | protein_coding | |
| Synonyms | MAGEA1|MGC9326|CT1.1 | |
| UniProtAcc | P43355 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for MAGEA1 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| MAGEA1 | 9.08e+01 | 2.92e+00 | 4.33e-01 | 6.75e+00 | 1.50e-11 | 2.84e-09 | LUAD |
| MAGEA1 | 2.22e+02 | 1.96e+00 | 4.94e-01 | 3.98e+00 | 7.02e-05 | 1.14e-03 | HNSC |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| MAGEA1 | 4.05e+02 | 1.13e+01 | 1.77e+00 | 6.38e+00 | 1.79e-10 | 1.82e-08 | ESCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| MAGEA1 | 7.26e+01 | 7.23e+00 | 5.04e-01 | 1.44e+01 | 1.05e-46 | 9.55e-46 | BRCA |
Top |
Sex-biased somatic mutation for MAGEA1 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for MAGEA1 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg10066681 | chrX:153179227 | CGI:chrX:153126233-153127047 | promoter | 8.92e-01 | 7.75e-01 | 6.48e+00 | 9.14e-11 | 1.19e-09 | 1.17e-01 |
| LUAD | cg05031352 | chrX:153179220 | CGI:chrX:153126233-153127047 | promoter | 8.80e-01 | 7.60e-01 | 6.62e+00 | 3.52e-11 | 4.67e-10 | 1.19e-01 |
| LGG | cg15037594 | chrX:153180184 | CGI:chrX:153126233-153127047 | promoter,gene body | 8.01e-01 | 9.30e-01 | -1.31e+01 | 2.12e-39 | 1.93e-38 | -1.29e-01 |
| LGG | cg13494652 | chrX:153178932 | CGI:chrX:153126233-153127047 | promoter | 6.70e-01 | 8.28e-01 | -1.14e+01 | 3.76e-30 | 3.00e-29 | -1.58e-01 |
| LGG | cg26414720 | chrX:153177937 | CGI:chrX:153126233-153127047 | promoter | 7.10e-01 | 9.07e-01 | -1.75e+01 | 2.71e-68 | 4.09e-67 | -1.97e-01 |
| BLCA | cg05031352 | chrX:153179220 | CGI:chrX:153126233-153127047 | promoter | 6.46e-01 | 5.43e-01 | 3.30e+00 | 9.83e-04 | 5.10e-03 | 1.03e-01 |
| LIHC | cg10066681 | chrX:153179227 | CGI:chrX:153126233-153127047 | promoter | 6.06e-01 | 5.02e-01 | 3.20e+00 | 1.38e-03 | 4.67e-03 | 1.04e-01 |
| LIHC | cg05031352 | chrX:153179220 | CGI:chrX:153126233-153127047 | promoter | 6.07e-01 | 5.02e-01 | 3.28e+00 | 1.03e-03 | 3.81e-03 | 1.05e-01 |
| KIRP | cg13494652 | chrX:153178932 | CGI:chrX:153126233-153127047 | promoter | 6.95e-01 | 8.00e-01 | -4.71e+00 | 2.53e-06 | 2.64e-05 | -1.05e-01 |
| PCPG | cg10066681 | chrX:153179227 | CGI:chrX:153126233-153127047 | promoter | 7.69e-01 | 6.40e-01 | 3.16e+00 | 1.56e-03 | 5.55e-03 | 1.29e-01 |
| PCPG | cg05031352 | chrX:153179220 | CGI:chrX:153126233-153127047 | promoter | 7.93e-01 | 6.63e-01 | 3.35e+00 | 8.11e-04 | 3.09e-03 | 1.30e-01 |
| GBM | cg26414720 | chrX:153177937 | CGI:chrX:153126233-153127047 | promoter | 6.28e-01 | 7.85e-01 | -2.60e+00 | 9.40e-03 | 2.37e-02 | -1.57e-01 |
| ESCA | cg05031352 | chrX:153179220 | CGI:chrX:153126233-153127047 | promoter | 7.48e-01 | 6.15e-01 | 2.08e+00 | 3.75e-02 | 4.65e-02 | 1.33e-01 |
| CHOL | cg26414720 | chrX:153177937 | CGI:chrX:153126233-153127047 | promoter | 7.26e-01 | 8.48e-01 | -2.48e+00 | 1.30e-02 | 2.54e-02 | -1.22e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg10066681 | chrX:153179227 | CGI:chrX:153126233-153127047 | promoter | 7.75e-01 | 9.74e-01 | -2.85e+00 | 4.31e-03 | 6.62e-03 | -1.98e-01 |
| LUAD | cg05031352 | chrX:153179220 | CGI:chrX:153126233-153127047 | promoter | 7.60e-01 | 9.67e-01 | -3.20e+00 | 1.37e-03 | 2.53e-03 | -2.07e-01 |
| LUAD | cg23776892 | chrX:153179461 | CGI:chrX:153126233-153127047 | promoter,gene body | 6.47e-01 | 8.15e-01 | -4.36e+00 | 1.27e-05 | 5.11e-05 | -1.67e-01 |
| LUAD | cg26414720 | chrX:153177937 | CGI:chrX:153126233-153127047 | promoter | 7.95e-01 | 8.98e-01 | -2.22e+00 | 2.68e-02 | 3.01e-02 | -1.03e-01 |
| LUSC | cg10066681 | chrX:153179227 | CGI:chrX:153126233-153127047 | promoter | 6.47e-01 | 9.71e-01 | -3.95e+00 | 7.91e-05 | 6.37e-04 | -3.24e-01 |
| LUSC | cg05031352 | chrX:153179220 | CGI:chrX:153126233-153127047 | promoter | 6.11e-01 | 9.62e-01 | -4.09e+00 | 4.34e-05 | 5.42e-04 | -3.50e-01 |
| LUSC | cg15037594 | chrX:153180184 | CGI:chrX:153126233-153127047 | promoter,gene body | 7.23e-01 | 9.32e-01 | -3.17e+00 | 1.52e-03 | 3.46e-03 | -2.09e-01 |
| LUSC | cg23776892 | chrX:153179461 | CGI:chrX:153126233-153127047 | promoter,gene body | 6.12e-01 | 8.11e-01 | -3.34e+00 | 8.25e-04 | 2.29e-03 | -1.99e-01 |
| LUSC | cg13494652 | chrX:153178932 | CGI:chrX:153126233-153127047 | promoter | 4.51e-01 | 6.91e-01 | -3.72e+00 | 1.98e-04 | 9.67e-04 | -2.40e-01 |
| LUSC | cg26414720 | chrX:153177937 | CGI:chrX:153126233-153127047 | promoter | 6.80e-01 | 9.06e-01 | -3.27e+00 | 1.08e-03 | 2.73e-03 | -2.26e-01 |
| ESCA | cg10066681 | chrX:153179227 | CGI:chrX:153126233-153127047 | promoter | 6.58e-01 | 9.27e-01 | -2.83e+00 | 4.67e-03 | 3.42e-02 | -2.69e-01 |
| ESCA | cg05031352 | chrX:153179220 | CGI:chrX:153126233-153127047 | promoter | 6.15e-01 | 8.85e-01 | -2.46e+00 | 1.38e-02 | 3.76e-02 | -2.70e-01 |
| ESCA | cg23776892 | chrX:153179461 | CGI:chrX:153126233-153127047 | promoter,gene body | 5.89e-01 | 7.44e-01 | -1.98e+00 | 4.82e-02 | 4.90e-02 | -1.55e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg10066681 | chrX:153179227 | CGI:chrX:153126233-153127047 | promoter | 7.44e-01 | 9.76e-01 | -1.09e+01 | 1.32e-27 | 1.46e-26 | -2.32e-01 |
| BRCA | cg05031352 | chrX:153179220 | CGI:chrX:153126233-153127047 | promoter | 7.32e-01 | 9.70e-01 | -1.04e+01 | 1.48e-25 | 1.32e-24 | -2.37e-01 |
| BRCA | cg15037594 | chrX:153180184 | CGI:chrX:153126233-153127047 | promoter,gene body | 6.81e-01 | 9.00e-01 | -9.31e+00 | 1.33e-20 | 7.55e-20 | -2.19e-01 |
| BRCA | cg23776892 | chrX:153179461 | CGI:chrX:153126233-153127047 | promoter,gene body | 5.81e-01 | 7.85e-01 | -1.14e+01 | 3.01e-30 | 4.51e-29 | -2.04e-01 |
| BRCA | cg13494652 | chrX:153178932 | CGI:chrX:153126233-153127047 | promoter | 5.38e-01 | 6.41e-01 | -7.24e+00 | 4.37e-13 | 1.38e-12 | -1.03e-01 |
| BRCA | cg26414720 | chrX:153177937 | CGI:chrX:153126233-153127047 | promoter | 6.16e-01 | 7.76e-01 | -8.08e+00 | 6.66e-16 | 2.60e-15 | -1.60e-01 |
| COAD | cg26414720 | chrX:153177937 | CGI:chrX:153126233-153127047 | promoter | 6.62e-01 | 7.98e-01 | -2.21e+00 | 2.72e-02 | 3.24e-02 | -1.36e-01 |
Top |
Exon skipping events with PSI in TCGA for MAGEA1 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for MAGEA1 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for MAGEA1 |
| TFs related to MAGEA1. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| ACC | SP2 | MAGEA1 | 3.28e+00 | 7.69e-03 | 4.17e+00 | 9.83e-01 | Female-biased |
| ACC | SP9 | MAGEA1 | 3.16e+00 | 7.23e-03 | 4.07e+00 | 9.82e-01 | Female-biased |
| ACC | ZFX | MAGEA1 | 2.87e+00 | 3.56e-03 | 3.94e+00 | 9.83e-01 | Female-biased |
| ACC | ZNF765 | MAGEA1 | 2.89e+00 | 4.24e-03 | 3.92e+00 | 9.82e-01 | Female-biased |
| DLBC | KLF15 | MAGEA1 | 3.25e+00 | 5.20e-03 | 4.32e+00 | 9.86e-01 | Female-biased |
| DLBC | MAZ | MAGEA1 | 3.31e+00 | 3.06e-03 | 4.53e+00 | 9.91e-01 | Female-biased |
| DLBC | PRDM9 | MAGEA1 | 3.20e+00 | 5.95e-03 | 4.23e+00 | 9.84e-01 | Female-biased |
| DLBC | SP1 | MAGEA1 | 3.30e+00 | 3.77e-03 | 4.47e+00 | 9.89e-01 | Female-biased |
| DLBC | VEZF1 | MAGEA1 | 3.33e+00 | 3.90e-03 | 4.48e+00 | 9.89e-01 | Female-biased |
| DLBC | WT1 | MAGEA1 | 3.05e+00 | 5.55e-03 | 4.09e+00 | 9.82e-01 | Female-biased |
| DLBC | ZBTB17 | MAGEA1 | 3.27e+00 | 2.67e-03 | 4.53e+00 | 9.91e-01 | Female-biased |
| DLBC | ZNF180 | MAGEA1 | 3.38e+00 | 6.14e-03 | 4.41e+00 | 9.86e-01 | Female-biased |
| DLBC | ZNF263 | MAGEA1 | 3.19e+00 | 6.11e-03 | 4.21e+00 | 9.83e-01 | Female-biased |
| DLBC | ZNF341 | MAGEA1 | 3.39e+00 | 7.16e-03 | 4.37e+00 | 9.85e-01 | Female-biased |
| DLBC | ZNF432 | MAGEA1 | 3.37e+00 | 4.94e-03 | 4.46e+00 | 9.88e-01 | Female-biased |
| DLBC | ZNF443 | MAGEA1 | 3.17e+00 | 1.48e-03 | 4.61e+00 | 9.93e-01 | Female-biased |
| DLBC | ZNF467 | MAGEA1 | 3.37e+00 | 4.20e-03 | 4.51e+00 | 9.89e-01 | Female-biased |
| DLBC | ZNF880 | MAGEA1 | 3.31e+00 | 5.72e-03 | 4.36e+00 | 9.86e-01 | Female-biased |
| DLBC | ZNF98 | MAGEA1 | 3.11e+00 | 2.12e-03 | 4.43e+00 | 9.91e-01 | Female-biased |
| MAGEA1 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for MAGEA1 |
| RBPs related to ES in MAGEA1. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| MAGEA1 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000198681 |
| CpG Site: cg10066681 | |
| Position to Gene: promoter | |
| Male Effect: -0.250829379931274 | |
| Female Effect: - | |
 | Gene ID: ENSG00000198681 |
| CpG Site: cg05031352 | |
| Position to Gene: promoter | |
| Male Effect: -0.256479074082562 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg10066681 | chrX:153179227 | promoter | -0.250829379931274 | 8.46301012685687e-25 | -0.6549636550288722 | 1.0487464410927734e-28 | LUAD |
| cg05031352 | chrX:153179220 | promoter | -0.256479074082562 | 1.1569811156714e-12 | -0.5080504864403019 | 4.898807917779711e-16 | LUAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of MAGEA1 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000198681 | MAGEA1 | C0025202 | melanoma | 1 | CTD_human |
| ENSG00000198681 | MAGEA1 | C2239176 | Liver carcinoma | 1 | CTD_human |
